🇺🇸 FDA
Patent

US 11213582

Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits

granted A61KA61K2039/545A61K2039/55516

Quick answer

US patent 11213582 (Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits) held by The Regents of the University of California expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/545, A61K2039/55516, A61K2039/55522, A61K2039/55561